Menu

Cystic Fibrosis (CF)

Cystic Fibrosis (CF) is the most common genetically determined, early onset and still lethal disease. CF affects approximately one in 2,500 newborns in Germany. With improvements in symptomatic therapies and standardized CF medical care, the median survival age of CF patients in Germany has risen to approximately 40 years. However, despite recent breakthroughs in disease-modifying therapies for a small subgroup of patients with specific CF geno types, there are currently no therapies available to the majority of patients that target CF lung disease at its root. The overall aim of the DZL CF research program is to advance the current understanding of the pathogenesis of CF lung disease and to use this knowledge to improve CF diagnostics, to develop more sensitive tools for monitoring of disease activity, and novel strategies for the effective prevention and therapy of CF lung disease.

Scientific Coordinators of the Disease Area

Prof. Dr. Marcus Mall (BIH)
Prof. Dr. Burkhard Tümmler (BREATH)

Administrative Coordinator of the Disease Area

Dr. Birgit Teucher (TLRC)

Participating DZL Partner Sites

ARCN, BREATH, TLRC, UGMLC

News about Cystic Fibrosis (CF)

30. August 2021

MRI technique is suitable for detecting progression of cystic fibrosis in preschool children & benefits of newborn screening

Regular examination of the lungs using magnetic resonance imaging (MRI) can detect how lung disease develops in children with cystic fibrosis.
Read More
26. August 2021

Cystic Fibrosis – Increasing numbers of patients benefit from improved treatment

A clinical trial has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare disease-causing genetic defects.
Read More
12. April 2021

DZL Funds Four More Clinical Trials – Significant Contribution to Translational Research

Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be funded as of 2021.
Read More
All Cystic Fibrosis (CF) news
chevron-down